10 Biotech Stocks to Buy According to Wall Street Analysts

7. Cytokinetics Incorporated (NASDAQ:CYTK)

Number of Hedge Fund Holders: 64

Average Upside Potential as of July 30: 93.48%

Cytokinetics Incorporated (NASDAQ:CYTK) is one of the biotech stocks to buy according to Wall Street analysts. On July 10, Cytokinetics announced that five presentations related to their investigational drug, called aficamten, will be delivered at the European Society of Cardiology/ESC Congress 2025. The congress is scheduled to take place in Madrid, Spain, from August 29 to September 1 this year.

Aficamten is a cardiac myosin inhibitor designed to reduce the hypercontractility associated with hypertrophic cardiomyopathy/HCM. Among the key presentations, a “Hot Line” presentation on August 30 will detail the primary results from the MAPLE-HCM study. The study compares aficamten to metoprolol in patients with obstructive HCM, focusing on Left Ventricular Outflow Tract/LVOT obstruction and exercise capacity.

Additionally, a “Late Breaking Clinical Science” session on August 31 will feature data on the incidence and impact of atrial fibrillation across three clinical trials of aficamten in obstructive HCM: REDWOOD-HCM, SEQUOIA-HCM, and FOREST-HCM. Another oral presentation on August 31 will cover the efficacy and safety of long-term treatment with aficamten in symptomatic obstructive HCM, drawing results specifically from the FOREST-HCM study.

Cytokinetics Incorporated (NASDAQ:CYTK) is a late-stage biopharmaceutical company that focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases in the US.